Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Molecular Epidemiology of HIV-1 Subtype G in the Russian Federation.

Murzakova A, Kireev D, Baryshev P, Lopatukhin A, Serova E, Shemshura A, Saukhat S, Kolpakov D, Matuzkova A, Suladze A, Nosik M, Eremin V, Shipulin G, Pokrovsky V.

Viruses. 2019 Apr 16;11(4). pii: E348. doi: 10.3390/v11040348.

2.

Inhibition of telomerase activity by splice-switching oligonucleotides targeting the mRNA of the telomerase catalytic subunit affects proliferation of human CD4+ T lymphocytes.

Zhdanov DD, Plyasova AA, Gladilina YA, Pokrovsky VS, Grishin DV, Grachev VA, Orlova VS, Pokrovskaya MV, Alexandrova SS, Lobaeva TA, Sokolov NN.

Biochem Biophys Res Commun. 2019 Feb 12;509(3):790-796. doi: 10.1016/j.bbrc.2018.12.186. Epub 2019 Jan 4.

PMID:
30612734
3.

Endonuclease G modulates the alternative splicing of deoxyribonuclease 1 mRNA in human CD4+ T lymphocytes and prevents the progression of apoptosis.

Zhdanov DD, Gladilina YA, Pokrovsky VS, Grishin DV, Grachev VA, Orlova VS, Pokrovskaya MV, Alexandrova SS, Plyasova AA, Sokolov NN.

Biochimie. 2019 Feb;157:158-176. doi: 10.1016/j.biochi.2018.11.020. Epub 2018 Dec 3.

PMID:
30521874
4.

Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion.

Pokrovsky VS, Vinnikov D.

Expert Rev Anticancer Ther. 2018 Nov 19:1-12. doi: 10.1080/14737140.2019.1549992. [Epub ahead of print]

PMID:
30449214
5.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
6.

Expert consensus statement on the science of HIV in the context of criminal law.

Barré-Sinoussi F, Abdool Karim SS, Albert J, Bekker LG, Beyrer C, Cahn P, Calmy A, Grinsztejn B, Grulich A, Kamarulzaman A, Kumarasamy N, Loutfy MR, El Filali KM, Mboup S, Montaner JS, Munderi P, Pokrovsky V, Vandamme AM, Young B, Godfrey-Faussett P.

J Int AIDS Soc. 2018 Jul;21(7):e25161. doi: 10.1002/jia2.25161.

7.

Contact-independent suppressive activity of regulatory T cells is associated with telomerase inhibition, telomere shortening and target lymphocyte apoptosis.

Zhdanov DD, Gladilina YA, Grishin DV, Grachev VA, Orlova VS, Pokrovskaya MV, Alexandrova SS, Pokrovsky VS, Sokolov NN.

Mol Immunol. 2018 Sep;101:229-244. doi: 10.1016/j.molimm.2018.07.017. Epub 2018 Jul 17.

PMID:
30025223
8.

Murine regulatory T cells induce death of effector T, B, and NK lymphocytes through a contact-independent mechanism involving telomerase suppression and telomere-associated senescence.

Zhdanov DD, Gladilina YA, Pokrovsky VS, Grishin DV, Grachev VA, Orlova VS, Pokrovskaya MV, Alexandrova SS, Sokolov NN.

Cell Immunol. 2018 Sep;331:146-160. doi: 10.1016/j.cellimm.2018.06.008. Epub 2018 Jun 19.

PMID:
29935763
9.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
10.

Optimization of Polycistronic Anti-CCR5 Artificial microRNA Leads to Improved Accuracy of Its Lentiviral Vector Transfer and More Potent Inhibition of HIV-1 in CD4⁺ T-Cells.

Urusov F, Glazkova D, Omelchenko D, Bogoslovskaya E, Tsyganova G, Kersting K, Shipulin G, Pokrovsky V.

Cells. 2018 Feb 4;7(2). pii: E10. doi: 10.3390/cells7020010.

11.

Amino Acid Degrading Enzymes and their Application in Cancer Therapy.

Pokrovsky VS, Chepikova OE, Davydov DZ, Zamyatnin AA Jr, Lukashev AN, Lukasheva EV.

Curr Med Chem. 2019;26(3):446-464. doi: 10.2174/0929867324666171006132729. Review.

PMID:
28990519
12.

Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum L-asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes.

Zhdanov DD, Pokrovsky VS, Pokrovskaya MV, Alexandrova SS, Eldarov MA, Grishin DV, Basharov MM, Gladilina YA, Podobed OV, Sokolov NN.

Cancer Med. 2017 Nov;6(11):2697-2712. doi: 10.1002/cam4.1218. Epub 2017 Oct 5.

13.

Tuberculosis and HIV/AIDS: the alien and the predator.

Pokrovsky V.

Lancet. 2017 Sep 30;390(10102):1618-1619. doi: 10.1016/S0140-6736(17)32384-X. Epub 2017 Sep 28. No abstract available.

PMID:
28980964
14.

Rhodospirillum rubruml-asparaginase targets tumor growth by a dual mechanism involving telomerase inhibition.

Zhdanov DD, Pokrovsky VS, Pokrovskaya MV, Alexandrova SS, Eldarov MA, Grishin DV, Basharov MM, Gladilina YA, Podobed OV, Sokolov NN.

Biochem Biophys Res Commun. 2017 Oct 14;492(2):282-288. doi: 10.1016/j.bbrc.2017.08.078. Epub 2017 Aug 23.

PMID:
28837806
15.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team.

Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17. Erratum in: Lancet HIV. 2017 Dec;4(12 ):e535.

PMID:
28729158
16.

L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis.

Pokrovsky VS, Vinnikov D.

Expert Rev Anticancer Ther. 2017 Aug;17(8):759-768. doi: 10.1080/14737140.2017.1344100. Epub 2017 Jun 21. Review.

PMID:
28621166
17.

Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.

Pokrovsky VS, Kazanov MD, Dyakov IN, Pokrovskaya MV, Aleksandrova SS.

BMC Cancer. 2016 Feb 11;16:89. doi: 10.1186/s12885-016-2125-4.

18.

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team.

PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.

19.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team.

Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum in: Lancet. 2014 Jan 4;383(9911):30.

PMID:
23830355
20.

Enzymatic properties and anticancer activity of L-lysine α-oxidase from Trichoderma cf. aureoviride Rifai BKMF-4268D.

Pokrovsky VS, Treshalina HM, Lukasheva EV, Sedakova LA, Medentzev AG, Arinbasarova AY, Berezov TT.

Anticancer Drugs. 2013 Sep;24(8):846-51. doi: 10.1097/CAD.0b013e328362fbe2.

PMID:
23777857

Supplemental Content

Loading ...
Support Center